NCT06630247
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06630247
Title A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Exelixis
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Exelixis Clinical Site #4 Denver Colorado 80218 United States Details
Exelixis Clinical Site #9 New Haven Connecticut 06511 United States Details
Exelixis Clinical Site #8 Washington D.C. District of Columbia 20007 United States Details
Exelixis Clinical Site #10 Jefferson Louisiana 70121 United States Details
Exelixis Clinical Site #7 New York New York 10029 United States Details
Exelixis Clinical SIte #2 Huntersville North Carolina 28078 United States Details
Exelixis Clinical Site #3 Nashville Tennessee 37203 United States Details
Exelixis Clinical Site #5 Nashville Tennessee 37203 United States Details
Exelixis Clinical Site #1 Austin Texas 78758 United States Details
Exelixis Clinical Site #6 Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field